Clinical Trials

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

Conditions:   Hypertension;   Obesity;   Stress, Psychological;   Blood Pressure
Interventions:   Drug: Irbesartan;   Other: Placebo
Sponsor:   Augusta University
Unknown status

Wed, 11 Mar 2015 12:00:00 EDT

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Condition:   Hypertension
Interventions:   Drug: Irbesartan/HCTZ;   Drug: Irbesartan monotherapy
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Thu, 04 Nov 2004 12:00:00 EST

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Condition:   Hypertension
Interventions:   Drug: Irbesartan;   Drug: Avapro
Sponsor:   Roxane Laboratories
Completed

Tue, 23 Oct 2012 12:00:00 EDT

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Condition:   Hypertension
Interventions:   Drug: Irbesartan;   Drug: Avapro
Sponsor:   Roxane Laboratories
Completed

Tue, 23 Oct 2012 12:00:00 EDT

A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin

Condition:   Healthy
Intervention:   Drug: HCP0912 / Irbesartan and Atorvastatin
Sponsor:   Hanmi Pharmaceutical Company Limited
Completed

Thu, 06 Oct 2011 12:00:00 EDT

Irbesartan and Adhesion Molecules in AF

Condition:   Persistent Atrial Fibrillation
Interventions:   Drug: irbesartan;   Drug: placebo
Sponsors:   University of Magdeburg;   Sanofi
Unknown status

Wed, 13 Feb 2008 12:00:00 EST

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

Condition:   Albuminuria
Interventions:   Drug: Ramipril + Irbesartan;   Drug: Ramipril + Placebo
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Wed, 03 Nov 2004 12:00:00 EST

Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Irbesartan;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Fri, 14 Jul 2006 12:00:00 EDT

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Condition:   Type 2 Diabetic Nephropathy
Interventions:   Drug: Alfacalcidol;   Drug: Irbesartan
Sponsor:   The Third Xiangya Hospital of Central South University
Completed

Wed, 10 May 2017 12:00:00 EDT

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Conditions:   Metabolic Syndrome;   Hypertension
Interventions:   Drug: Irbesartan;   Drug: Hydrochlorothiazide
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Tue, 10 May 2005 12:00:00 EDT

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Condition:   Hypertension
Interventions:   Drug: Irbesartan/HCTZ;   Drug: Irbesartan monotherapy;   Drug: HCTZ monotherapy
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Mon, 08 Nov 2004 12:00:00 EST

Irbesartan in Hypertension

Condition:   Hypertension
Intervention:   Drug: Irbesartan
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Thu, 15 Dec 2005 12:00:00 EST

Bariatric Surgery and Pharmacokinetics of Irbesartan

Condition:   Obesity, Morbid
Intervention:   Drug: Irbesartan
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Volvat Medisinsk Senter Stokkan;   Namsos Hospital;   Alesund Hospital
Recruiting

Mon, 26 Mar 2018 12:00:00 EDT

Irbesartan Versus Amlodipine: The OBI Study

Conditions:   Obesity;   Hypertension
Interventions:   Drug: Irbesartan;   Drug: Amlodipine
Sponsor:   Aristotle University Of Thessaloniki
Withdrawn

Thu, 01 Oct 2009 12:00:00 EDT

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy

Condition:   Hypertension
Interventions:   Drug: irbesartan/amlodipine;   Drug: irbesartan
Sponsor:   Sanofi
Completed

Wed, 12 Aug 2009 12:00:00 EDT

Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan

Condition:   Kidney Failure, Chronic
Interventions:   Drug: Irbesartan;   Drug: Placebo matching irbesartan 150 mg
Sponsor:   University of Aarhus
Completed

Mon, 17 Nov 2008 12:00:00 EST

Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects

Condition:   Healthy
Interventions:   Drug: Gemigliptin;   Drug: Irbesartan
Sponsor:   LG Life Sciences
Completed

Mon, 08 Apr 2013 12:00:00 EDT

Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria

Condition:   Hypertension
Intervention:   Drug: Irbesartan
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Thu, 08 Jun 2006 12:00:00 EDT

Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Intervention:   Drug: Irbesartan
Sponsors:   University of Erlangen-Nürnberg Medical School;   Bristol-Myers Squibb
Completed

Fri, 09 Sep 2005 12:00:00 EDT

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Condition:   Hypertension
Interventions:   Drug: Irbesartan and Hydrochlorothiazide;   Drug: Avalide
Sponsor:   Roxane Laboratories
Completed

Tue, 23 Oct 2012 12:00:00 EDT

Irbesartan and Atenolol in Hypertensive Heart Disease

Condition:   Hypertension
Interventions:   Drug: Irbesartan;   Drug: Atenolol
Sponsors:   Karolinska Institutet;   Bristol-Myers Squibb;   Sanofi;   Swedish Heart Lung Foundation
Completed

Wed, 18 Oct 2006 12:00:00 EDT

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

Condition:   Hypertension
Interventions:   Drug: Irbesartan and Hydrochlorothiazide;   Drug: Avalide
Sponsor:   Roxane Laboratories
Completed

Tue, 23 Oct 2012 12:00:00 EDT

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Condition:   Essential Hypertension
Intervention:   Drug: Irbesartan/Amlodipine
Sponsor:   Handok Inc.
Recruiting

Tue, 28 Jul 2020 12:00:00 EDT

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy

Condition:   Hypertension
Interventions:   Drug: irbesartan/amlodipine;   Drug: amlodipine
Sponsor:   Sanofi
Completed

Tue, 11 Aug 2009 12:00:00 EDT

Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing

Condition:   Hypertension
Interventions:   Drug: Irbesartan/Hydrochlorothiazide;   Drug: Irbesartan
Sponsor:   Sanofi
Completed

Tue, 06 Mar 2007 12:00:00 EST

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Condition:   Hypertension
Interventions:   Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg;   Drug: Irbesartan 150mg
Sponsor:   Sanofi
Completed

Thu, 19 Feb 2009 12:00:00 EST

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Irbesartan/atorvastatin fixed dose combination;   Drug: Irbesartan SR47436;   Drug: Atorvastatin
Sponsor:   Sanofi
Completed

Fri, 22 Jul 2016 12:00:00 EDT

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Condition:   Myocardial Infarction
Intervention:   Drug: Irbesartan Oral Tablet
Sponsors:   University of Southern Denmark;   Bristol-Myers Squibb
Completed

Mon, 01 Aug 2005 12:00:00 EDT

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Conditions:   Atrial Fibrillation;   Cardiovascular Disease
Interventions:   Drug: Irbesartan;   Drug: placebo
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Mon, 07 Nov 2005 12:00:00 EST

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Condition:   Focal Segmental Glomerulosclerosis
Interventions:   Drug: sparsentan;   Drug: Irbesartan
Sponsor:   Travere Therapeutics, Inc.
Active, not recruiting

Tue, 10 Apr 2018 12:00:00 EDT

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Condition:   Immunoglobulin A Nephropathy
Interventions:   Drug: sparsentan;   Drug: irbesartan
Sponsor:   Travere Therapeutics, Inc.
Active, not recruiting

Tue, 04 Dec 2018 12:00:00 EST

APROVE : Irbesartan in Hypertension

Condition:   Hypertension
Intervention:   Drug: Irbesartan
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Fri, 27 Jan 2006 12:00:00 EST

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Irbesartan;   Drug: placebo
Sponsors:   ANRS, Emerging Infectious Diseases;   Sanofi
Completed

Thu, 15 Dec 2005 12:00:00 EST

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Condition:   Focal Segmental Glomerulosclerosis
Interventions:   Drug: RE-021 (Sparsentan);   Drug: Irbesartan
Sponsor:   Travere Therapeutics, Inc.
Active, not recruiting

Wed, 06 Jun 2012 12:00:00 EDT

Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

Condition:   Hypertension
Interventions:   Drug: IRBESARTAN;   Drug: Atenolol
Sponsor:   Sanofi
Completed

Fri, 14 Sep 2007 12:00:00 EDT

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Condition:   Hypertension
Intervention:   Drug: Irbesartan (Aprovel)
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Wed, 09 Aug 2006 12:00:00 EDT

ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation

Conditions:   Myocardial Ischemia;   Hypertension
Intervention:   Drug: Irbesartan
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Fri, 24 Feb 2006 12:00:00 EST

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Condition:   Hypertension
Intervention:   Drug: Irbesartan (Aprovel)
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Mon, 12 Jun 2006 12:00:00 EDT

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Condition:   Hypertension
Intervention:   Drug: Irbesartan (Aprovel)
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Wed, 09 Aug 2006 12:00:00 EDT

Angiotensin II Antagonist in Severe Sepsis

Condition:   Severe Sepsis
Intervention:   Drug: Irbesartan
Sponsors:   University of Salerno;   Federico II University
Unknown status

Mon, 25 Nov 2013 12:00:00 EST

Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Condition:   Hypertension
Intervention:   Drug: irbesartan/hydrochlorothiazide
Sponsor:   Sanofi
Completed

Fri, 02 May 2008 12:00:00 EDT

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

Condition:   Ehlers-Danlos Syndrome, Vascular Type
Interventions:   Drug: Irbesartan;   Drug: Placebo
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Ministry of Health, France
Completed

Thu, 05 Nov 2015 12:00:00 EST

Irbesartan and Amlodipine Combination in Controlling Blood Pressure

Condition:   Hypertension
Interventions:   Drug: IRBESARTAN (SR47436);   Drug: Amlodipine;   Drug: Irbesartan / Amlodipine;   Drug: Placebo
Sponsor:   Sanofi
Completed

Fri, 31 Jul 2009 12:00:00 EDT

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Condition:   Hypertension
Interventions:   Drug: Irbesartan/Amlodipine (150/5mg);   Drug: Irbesartan/Amlodipine (150/10mg);   Drug: Irbesartan/Amlodipine (300/5mg);   Drug: Irbesartan/Amlodipine (300/10mg)
Sponsor:   Sanofi
Completed

Thu, 21 Jun 2012 12:00:00 EDT

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Condition:   Congestive Heart Failure
Interventions:   Drug: Irbesartan;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Sanofi
Completed

Tue, 02 Nov 2004 12:00:00 EST

ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination

Condition:   Hypertension
Intervention:   Drug: Irbesartan - Hydrochlorothiazide
Sponsor:   Sanofi
Completed

Wed, 02 Jul 2008 12:00:00 EDT

Drug Interaction Between Irbesartan and Hydrochlorothiazide

Condition:   Healthy
Interventions:   Drug: Irbeasartan/hydrochlorothiazide;   Drug: Irbesartan;   Drug: Hydrochlorothiazide
Sponsor:   Damanhour University
Completed

Tue, 21 May 2013 12:00:00 EDT

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Condition:   Hypertension
Interventions:   Drug: irbesartan;   Drug: placebo;   Drug: PS433540
Sponsor:   Ligand Pharmaceuticals
Completed

Thu, 13 Mar 2008 12:00:00 EDT

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Conditions:   Hypertension;   Hyperlipidemia
Interventions:   Drug: Irbesartan/Atorvastatin A;   Drug: Irbesartan;   Drug: Atorvastatin A;   Drug: Placebo;   Drug: Irbesartan/Atorvastatin B;   Drug: Atorvastatin B
Sponsor:   Hanmi Pharmaceutical Company Limited
Completed

Thu, 29 Sep 2011 12:00:00 EDT

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Condition:   Hypertension
Interventions:   Drug: valsartan;   Drug: irbesartan
Sponsor:   Novartis
Completed

Thu, 15 Sep 2005 12:00:00 EDT

Remission Clinic in Proteinuric Chronic Nephropathies

Condition:   Chronic Kidney Disease
Intervention:   Drug: Ramipril, Irbesartan and Atorvastin
Sponsor:   Mario Negri Institute for Pharmacological Research
Active, not recruiting

Tue, 29 Mar 2016 12:00:00 EDT

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

Conditions:   Preeclampsia;   Pregnancy Induced Hypertension
Intervention:   Drug: Irbesartan
Sponsor:   Brigham and Women's Hospital
Suspended

Thu, 26 Jan 2012 12:00:00 EST

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Aliskiren;   Drug: Irbesartan;   Drug: Captopril
Sponsor:   Novartis
Completed

Thu, 17 Apr 2008 12:00:00 EDT

The Oxford Marfan Trial

Condition:   Marfan Syndrome
Interventions:   Drug: Irbesartan 150-300mg capsules daily for 6 months;   Drug: Doxycycline 100-200mg capsules daily for 6 months;   Drug: Doxycycline placebo capsules daily for 6 months;   Drug: Irbesartan placebo capsules daily for 6 months
Sponsors:   University of Oxford;   Oxford University Hospitals NHS Trust
Unknown status

Tue, 24 Sep 2013 12:00:00 EDT

Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension

Condition:   Hypertension
Interventions:   Drug: Irbesartan/hydrochlorothiazide;   Drug: Valsartan/hydrochlorothiazide;   Drug: Hydrochlorothiazide
Sponsor:   Sanofi
Completed

Thu, 12 Jul 2007 12:00:00 EDT

Sevelamer in Proteinuric CKD

Condition:   Chronic Kidney Disease
Interventions:   Drug: Sevelamer;   Drug: Ramipril and Irbesartan
Sponsor:   Mario Negri Institute for Pharmacological Research
Completed

Thu, 24 Oct 2013 12:00:00 EDT

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Conditions:   Abdominal Obesity;   Hypertension
Interventions:   Drug: Moxonidine;   Drug: Irbesartan
Sponsor:   Baker Heart and Diabetes Institute
Unknown status

Thu, 26 May 2011 12:00:00 EDT

Combined Antihypertensive Therapy and Sexual Dysfunction

Conditions:   Hypertension;   Sexual Dysfunction
Interventions:   Drug: Felodipine add Irbesartan;   Drug: Felodipine add Metoprolol
Sponsor:   LanZhou University
Unknown status

Thu, 11 Nov 2010 12:00:00 EST

PHARES Study: Management of Resistant Hypertension

Condition:   Hypertension
Intervention:   Drug: irbesartan, amlodipine and hydrochlorothiazide
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed

Fri, 23 Sep 2005 12:00:00 EDT

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Condition:   Obesity and Glomerulopathy
Interventions:   Drug: High dosage Sevelamer Carbonate + Irbesartan;   Drug: Low dosage Sevelamer Carbonate + Irbesartan;   Drug: Irbesartan
Sponsor:   Zhi-Hong Liu, M.D.
Terminated

Thu, 31 Dec 2015 12:00:00 EST

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Placebo drug that simulates Irbesartan tablets;   Drug: irbesartan tablets;   Drug: Placebo drug that simulates HuangKui capsule;   Drug: HuangKui Capsule
Sponsor:   Jiangsu Famous Medical Technology Co., Ltd.
Unknown status

Wed, 11 Jan 2017 12:00:00 EST

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Condition:   Hypertension
Interventions:   Drug: ALN-AGT01;   Drug: ALN-AGT01-Matching Placebo;   Drug: Irbesartan;   Drug: Irbesartan-Matching Placebo
Sponsor:   Alnylam Pharmaceuticals
Recruiting

Wed, 01 May 2019 12:00:00 EDT

Multiple Treatments for Ebola Virus Disease (EVD)

Condition:   Ebola Virus Disease
Interventions:   Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
Sponsors:   Clinical Research Management, Inc.;   Bill and Melinda Gates Foundation;   Duke University;   University of Sierra Leone;   Syneos Health;   University of North Carolina
Unknown status

Thu, 05 Mar 2015 12:00:00 EST

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

Condition:   Hypertension
Intervention:   Drug: aliskiren
Sponsor:   Novartis
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study

Conditions:   Hypertension;   Metabolic Syndrome
Intervention:  
Sponsor:   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Unknown status

Tue, 09 Mar 2010 12:00:00 EST

Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction

Conditions:   Hypertension;   Cardiac Arrhythmias;   Diabetes Mellitus;   Renal Insufficiency;   Sleep Apnea
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Completed

Thu, 29 May 2014 12:00:00 EDT

Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.

Condition:   Arterial Hypertension
Intervention:  
Sponsor:   Russian Heart Failure Society
Completed

Fri, 30 Dec 2016 12:00:00 EST

Role of AT1-receptor Blockers in Insulin-induced Vasodilation.

Conditions:   Hypertension;   Insulin Resistance;   Microcirculation
Interventions:   Drug: Irbesartan;   Drug: Felodipine;   Drug: Placebo
Sponsor:   Maastricht University Medical Center
Unknown status

Wed, 27 Aug 2008 12:00:00 EDT

Prevention of Kidney Transplant Rejection

Conditions:   End-Stage Renal Disease;   Chronic Allograft Nephropathy
Interventions:   Drug: Irbesartan;   Drug: Pravastatin
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Fri, 31 Aug 2001 12:00:00 EDT

Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria

Conditions:   Diabetes;   Hypertensive Disease
Interventions:   Drug: Renin-angiotensin system blockers;   Drug: non-renin angiotensin system blockers
Sponsor:   Hospital Authority, Hong Kong
Unknown status

Wed, 28 Dec 2011 12:00:00 EST

Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Propagermanium;   Drug: Placebo
Sponsors:   Dimerix Bioscience Pty Ltd;   Iqvia Pty Ltd
Active, not recruiting

Mon, 13 Aug 2018 12:00:00 EDT

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Condition:   Focal Segmental Glomerulosclerosis
Interventions:   Drug: Propagermanium;   Drug: Placebo
Sponsors:   Dimerix Bioscience Pty Ltd;   Iqvia Pty Ltd
Active, not recruiting

Tue, 28 Aug 2018 12:00:00 EDT

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Conditions:   Atrial Fibrillation;   Vascular Risk
Interventions:   Drug: clopidogrel (SR25990C);   Drug: placebo
Sponsors:   Sanofi;   Bristol-Myers Squibb
Completed

Mon, 07 Nov 2005 12:00:00 EST

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Conditions:   Atrial Fibrillation;   Vascular Risk
Intervention:   Drug: clopidogrel (SR25990C)
Sponsors:   Sanofi;   Bristol-Myers Squibb
Terminated

Fri, 21 Oct 2005 12:00:00 EDT

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Condition:   Essential Hypertension
Intervention:   Drug: Aliskiren
Sponsor:   Novartis
Completed

Fri, 23 Jun 2006 12:00:00 EDT

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)

Condition:   IgA Nephropathy
Interventions:   Drug: irbesartan;   Drug: methylprednisolone (MP) or prednisone (pred);   Drug: mycophenolate mofetil (MMF)
Sponsor:   Sun Yat-sen University
Completed

Mon, 14 Apr 2008 12:00:00 EDT

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

Condition:   Metabolic Syndrome
Interventions:   Drug: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan;   Other: As selected by community physician
Sponsor:   Northwell Health
Terminated

Fri, 21 Nov 2008 12:00:00 EST

The Effects of Bindarit in Diabetic Nephropathy

Condition:   Diabetic Nephropathy
Interventions:   Drug: Bindarit;   Drug: Placebo
Sponsors:   Aziende Chimiche Riunite Angelini Francesco S.p.A;   Mario Negri Institute for Pharmacological Research
Completed

Fri, 23 Apr 2010 12:00:00 EDT

Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy

Condition:   Diabetic Nephropathy
Intervention:   Drug: Kunxian capsule
Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
Recruiting

Thu, 29 Jul 2021 12:00:00 EDT

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Conditions:   Renal Insufficiency, Chronic;   Hyperkalemia
Interventions:   Drug: Sodium Zirconium Cyclosilicate (SZC);   Drug: Placebo;   Drug: Lisinopril;   Drug: Valsartan;   Drug: Irbesartan
Sponsor:   AstraZeneca
Not yet recruiting

Fri, 24 Sep 2021 12:00:00 EDT

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Condition:   Kidney Transplantation
Interventions:   Drug: tacrolimus;   Biological: Simulect;   Drug: Cellcept;   Drug: Corticosteroids;   Drug: Ramipril;   Drug: Irbesartan
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Canada, Inc.
Completed

Tue, 07 Jul 2009 12:00:00 EDT

Coronavirus (COVID-19) ACEi/ARB Investigation

Conditions:   Hypertension;   COVID-19
Interventions:   Drug: Thiazide or Thiazide-like diuretics;   Drug: Calcium Channel Blockers;   Drug: ACE inhibitor;   Drug: Angiotensin receptor blocker
Sponsor:   National University of Ireland, Galway, Ireland
Suspended

Wed, 01 Apr 2020 12:00:00 EDT

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Condition:   Diabetic Nephropathy
Interventions:   Drug: SoC therapy;   Drug: irbesartan;   Drug: ramipril;   Drug: hydrochlorothiazide;   Drug: furosemide;   Drug: amlodipine;   Drug: atenolol;   Drug: doxazosin;   Drug: clonidine;   Drug: insulin;   Drug: simvastatin;   Drug: fibrate;   Drug: erythropoietin;   Drug: aspirin
Sponsor:   University of Campania "Luigi Vanvitelli"
Completed

Thu, 27 Sep 2007 12:00:00 EDT

Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples

Conditions:   Hypertension;   Diabetes Mellitus
Intervention:   Other: Nurse administered treatment algorithm
Sponsors:   Sunnybrook Health Sciences Centre;   Canadian Institutes of Health Research (CIHR);   Pfizer
Completed

Tue, 26 Aug 2008 12:00:00 EDT

Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients

Condition:   Sickle Cell Disease
Intervention:   Drug: RAS Inhibitors
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed

Mon, 06 Sep 2010 12:00:00 EDT

Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

Condition:   Hypertension
Interventions:   Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.;   Drug: renin guided therapeutics-no specific med. Any anti-hypertensive med.
Sponsors:   Medical University of South Carolina;   New York Presbyterian Hospital
Completed

Mon, 26 May 2008 12:00:00 EDT

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Conditions:   Diabetic Nephropathies;   Hypertension
Interventions:   Drug: Adalat XL;   Drug: Tiazac XC
Sponsor:   Bayer
Withdrawn

Fri, 11 Jul 2008 12:00:00 EDT

Renal Denervation in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Persistent Proteinuria With Type II Diabetes
Interventions:   Procedure: Percutaneous renal denervation and TMNS;   Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed

Tue, 01 May 2012 12:00:00 EDT

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

Conditions:   SARS-Cov-2;   COVID-19
Interventions:   Drug: Angiotensin Receptor Blockers;   Other: Placebo
Sponsor:   The George Institute
Recruiting

Tue, 19 May 2020 12:00:00 EDT

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Conditions:   Heart Failure, Systolic;   Frailty
Interventions:   Drug: sacubitril/valsartan;   Drug: Angiotensin II Receptor Blockers
Sponsor:   Brigham and Women's Hospital
Active, not recruiting

Mon, 08 Feb 2021 12:00:00 EST

Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Drug: rosuvastatin
Sponsor:   The Third Xiangya Hospital of Central South University
Unknown status

Mon, 20 Jul 2015 12:00:00 EDT

Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia

Conditions:   Hypertension;   Dyslipidemias
Interventions:   Drug: Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination));   Drug: Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
Sponsor:   Yonsei University
Completed

Tue, 20 Aug 2019 12:00:00 EDT

Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

Conditions:   Hypertension;   Hypertension Resistant to Conventional Therapy;   Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent
Interventions:   Device: Renal artery Angioplasty plus stenting.;   Drug: Anti hypertensive, statin and antiplatelet medication.
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Ministry of Health, France
Terminated

Thu, 03 Sep 2015 12:00:00 EDT

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Conditions:   Heart Diseases;   Diabetes Mellitus, Type 2
Interventions:   Drug: RAS-antagonist and beta-blocker up-to maximal dosages;   Other: RAS-antagonist and beta-blocker none or at stable dose
Sponsor:   Martin Huelsmann
Unknown status

Wed, 29 Jun 2016 12:00:00 EDT

Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics

Condition:   Hypertension
Intervention:   Other: Sevoflurane/oxygen/air/nitrous oxide
Sponsors:   Lawson Health Research Institute;   University of Western Ontario, Canada
Unknown status

Mon, 29 Oct 2012 12:00:00 EDT

Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

Conditions:   Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions:   Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Sponsors:   University of Vigo;   Servicio Gallego de Salud
Completed

Tue, 26 Aug 2008 12:00:00 EDT

Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)

Condition:   Chronic Renal Failure
Interventions:   Drug: ARB;   Drug: Pentoxifylline;   Drug: Placebo (for Pentoxifylline)
Sponsors:   National Taiwan University Hospital;   Far Eastern Memorial Hospital;   Mackay Memorial Hospital;   Taipei Medical University Hospital;   Shin Kong Wu Ho-Su Memorial Hospital;   Cathay General Hospital
Unknown status

Tue, 21 Jun 2011 12:00:00 EDT

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Conditions:   Hypertension;   COVID
Interventions:   Drug: ACEI/ARB;   Drug: Non-ACEI/ARB;   Drug: ACEI;   Drug: ARB
Sponsors:   University of Utah;   VA Salt Lake City Health Care System;   University of Pennsylvania;   Wake Forest University Health Sciences;   University of Florida;   Johns Hopkins Bloomberg School of Public Health;   Boston University;   Northwestern University;   Edith Nourse Rogers Memorial Veterans Hospital;   Columbia University;   MedStar Georgetown University Hospital
Completed

Mon, 13 Jul 2020 12:00:00 EDT